Gilead Sciences Completes Acquisition of MYR GmbH
Gilead Sciences, Inc. today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex ® which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus in adults with compensated liver disease in July 2020. … Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m. EST Cowen Annual Health Care Conference on Thursday, March 4, 2021 at 12:10 p.m. EST The live webcasts can be accessed at the company’s investors page at investors.gilead.com . The replays will be available for at .
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® in adult patients with relapsed or refractory large B-cell lymphoma . Results … Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF FOSTER CITY, Calif. & MECHELEN, Belgium (BUSINESS WIRE)
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings.
Investigators are being informed of the decision and they will be contacting their study participants to discontinue the investigational treatment.
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’s Clinical Programs Kite, a Gilead Company today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’s Clinical Development organization across hematological malignancies and solid tumors. Ken … Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’s Clinical Programs Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’s Clinical Development organization across hematological malignancies and solid tumors. Ken Takeshita, MD, has decided to leave the company to pursue another opportunity at t